DM
Therapeutic Areas
Biotron Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BIT225 | HIV‑1 | Phase 2 |
| Preclinical Program | Dengue Virus | Preclinical |
Leadership Team at Biotron
MM
Mr Michael J. Hoy
Chairman (Independent, Non‑Executive)
MM
Mr Michael Medway
Independent Director (Non‑Executive)
DP
Dr Paul Kasian
Independent Director (Non‑Executive)
DG
Dr Graeme Wald
Independent Director (Non‑Executive)
MM
Mr Marcelo Mora
Company Secretary